This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
Kerendia®▼ (finerenone) specialists’ resources
A visual overview of the Fidelio-DKD trial which demonstrated how Kerendia delayed CKD progression in adults with CKD associated with T2D vs placebo
This dosing card provides details on initiating treatment with Kerendia, dose adjustment and monitoring requirements.
Support with optimising the management of patients who have Chronic Kidney Disease (CKD) associated with Type 2 Diabetes (T2D).
This information pack may support you with your formulary application in England or Wales.
This information pack my support you with your formulary application in Scotland.
RP-KER-GB-1105 | January 2025
- Referencesexpand_less
- 1Bakris GL et al., N Engl J Med 2020; 383:2219-2229